The New Indian Express features Osteoboost’s FDA-cleared wearable, offering proactive, non-drug therapy to reduce bone loss in osteopenia patients.​

Women's Health cites Osteoboost’s Cofounder and Chief Scientific Officer Mike Jaasma on safe bone health strategies.

BHOF highlights Osteoboost’s FDA-cleared wearable, clinically proven to reduce spine bone loss by 85% in postmenopausal women with osteopenia.

PT Products Online announces Osteoboost’s pre-order launch; FDA-cleared wearable uses vibration therapy to reduce spine bone loss by 85% in women.

Longevity Live features Osteoboost, an FDA-cleared wearable delivering vibration therapy to reduce spinal bone loss by 85% in postmenopausal women.

Elite Wellness Oracle explores how Osteoboost’s innovative vibration therapy is changing the game for women seeking non-drug solutions to low bone density.

Healthcare Brew highlights Osteoboost’s FDA-cleared vibrating belt as a 2024 breakthrough, reducing spine bone loss in postmenopausal women.

Movement Logic Podcast reviews Osteoboost, an FDA-cleared wearable using vibration therapy to improve bone density in postmenopausal women.

Femtech Insider announces Osteoboost’s FDA-cleared wearable, now available for pre-order, offering non-drug vibration therapy to reduce spinal bone loss.

HIT Consultant announces Osteoboost’s FDA clearance and pre-order launch; wearable delivers vibration therapy to reduce spine bone loss in women.

Ubergizmo features Osteoboost, an FDA-cleared wearable using vibration therapy to reduce spine bone loss by 85% in postmenopausal women.

BHOF spotlights Osteoboost’s FDA-cleared wearable, offering non-drug vibration therapy to reduce bone loss in postmenopausal women with osteopenia.